Fuji Pharma Co., Ltd. (4554) AI Stock Analysis

• Market Cap: €31.69B
• Dividend Yield: 3.62%
• Average Volume (3M): 52.65K
• Price to Earnings (P/E): 9.9
• Beta (1Y): 0.68
• Revenue Growth: 13.46%
• EPS Growth: -46.40%
• Country: JP
• Employees: 1,658
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 12.08
• Shares Outstanding: 24,863,600
• 10 Day Avg. Volume: 39,780
• 30 Day Avg. Volume: 52,646
• PEG Ratio: -0.36
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 70 Outperform
• Price Target: ¥1,427.00 ▲(8.68%Upside)

Fuji Pharma's strengths lie in its strong financial performance and attractive valuation metrics, suggesting an undervalued stock with income potential. However, mixed technical indicators and challenges in cash flow management temper the overall score. Focus on cash flow improvement and monitoring technical trends could enhance its investment appeal.

Fuji Pharma Co., Ltd. Business Overview & Revenue Model

Company Description

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Fuji Pharma Co., Ltd. generates revenue through the sale of its pharmaceutical products, which include branded and generic drugs. The company's revenue streams are primarily driven by its offerings in women's healthcare, such as hormone medications and fertility treatments, as well as diagnostic drugs used in medical imaging. Additionally, Fuji Pharma leverages its research and development capabilities to innovate and expand its product line, further supporting its income. The company may also engage in strategic partnerships and collaborations with other pharmaceutical firms to enhance its market presence and share technological advancements, thereby contributing to its revenue growth.

Fuji Pharma Co., Ltd. Financial Statement Overview

Summary

Fuji Pharma shows strong revenue growth and solid balance sheet metrics, reflecting financial stability. However, challenges in maintaining net profit margins and managing cash flow indicate areas needing strategic improvement.

Income Statement

Fuji Pharma has demonstrated strong revenue growth with a notable increase from the previous period. The gross profit margin and EBIT margin remain solid at 40.3% and 10.9%, respectively, indicating effective cost management and operational efficiency. However, the net profit margin decreased from 13.3% to 9.1% TTM, reflecting some challenges in maintaining profitability levels.

Balance Sheet

The company maintains a healthy equity ratio of 50.6%, providing a strong buffer against liabilities. The debt-to-equity ratio is stable at 0.64, suggesting moderate leverage. Return on equity is robust at 9.2%, indicating effective utilization of shareholders' funds. However, the increase in total debt highlights potential risks if not managed carefully.

Cash Flow

While operating cash flow is currently unavailable, past performance indicates some fluctuations. The free cash flow has shown significant volatility, with periods of negative free cash flow, which may impact future investment capabilities. The lack of positive free cash flow to net income ratio underscores the need for improved cash management strategies.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
48.39B	46.14B	40.89B	35.43B	33.99B	33.79B
	Gross Profit
19.51B	17.84B	16.52B	14.56B	14.75B	14.87B
	EBIT
5.27B	3.88B	3.86B	3.78B	3.35B	3.14B
	EBITDA
8.50B	12.15B	7.54B	6.52B	5.46B	5.20B
	Net Income Common Stockholders
4.40B	6.15B	3.44B	2.70B	2.43B	2.08B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.70B	4.58B	2.32B	3.55B	10.20B	12.04B
	Total Assets
94.26B	90.00B	85.33B	75.54B	64.24B	61.96B
	Total Debt
30.41B	29.25B	28.95B	24.57B	18.66B	12.19B
	Net Debt
26.72B	24.67B	26.62B	21.02B	8.46B	149.00M
	Total Liabilities
46.50B	44.44B	44.16B	39.73B	31.56B	22.00B
	Stockholders Equity
47.76B	45.56B	41.17B	35.80B	32.68B	39.96B
Cash Flow		Free Cash Flow
0.00	-221.00M	-1.98B	-13.08B	2.10B	3.15B
	Operating Cash Flow
0.00	4.15B	1.92B	-658.00M	5.99B	5.77B
	Investing Cash Flow
0.00	-1.66B	-5.24B	-11.27B	-2.35B	-2.62B
	Financing Cash Flow
0.00	-435.00M	1.92B	5.09B	-5.43B	450.00M

Fuji Pharma Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1313.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4554, the sentiment is Positive. The current price of 1313 is above the 20-day moving average (MA) of 1288.10, above the 50-day MA of 1304.40, and below the 200-day MA of 1356.53, indicating a neutral trend. The MACD of -2.62 indicates Negative momentum. The RSI at 54.10 is Neutral, neither overbought nor oversold. The STOCH value of 56.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4554.

Fuji Pharma Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4554	70 Outperform	€31.69B	9.95	7.01%	3.62%	13.46%	-46.40%
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
TRXPF		$1.24B	28.25	4.56%	2.30%	―	―
TWAPF		$1.04B	10.01	11.38%	0.01%	―	―
MFY		€612.91M	18.06	4.35%	2.79%	―	―
4886	76 Outperform	¥61.26B	12.79		2.17%	2.06%	-32.48%
4569	73 Outperform	¥78.17B	9.39		0.67%	8.83%	70.61%